Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Detweiler Short K, Rajkumar SV, Larson D, Buardi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–8.PubMedCrossRef
2.
Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol 2010;195:1057–9.PubMedCrossRef
3.
Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361–6.PubMedCrossRef
4.
Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690–4.PubMedCrossRef
Metadata
Title
18F-FDG PET to identify soft tissue disease in multiple myeloma
Authors
Sharon F. Hain
Sobia Khan
William Stevenson
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1957-z

Other articles of this Issue 3/2012

European Journal of Nuclear Medicine and Molecular Imaging 3/2012 Go to the issue

Original Article

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts

Erratum

Erratum to: Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset

Editorial Commentary

18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?

Editorial Commentary

Myocardial perfusion imaging: a plus for coronary risk classification in diabetics

Editorial Commentary

Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice

Editorial Commentary

Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?